Top Markets
Coin of the day
Accelerate Diagnostics, Inc. Accelerate Diagnostics, Inc.

Accelerate Diagnostics, Inc.

AXDX
Rang in aandelen #40437
Accelerate Diagnostics, Inc. is an in vitro diagnostics company specializing in... Accelerate Diagnostics, Inc. is an in vitro diagnostics company specializing in solutions for the rapid diagnosis of critical infections, with operations spanning the United States, Europe, and the Middle East. The company's primary offering is the Accelerate Pheno system, an advanced in vitro diagnostic platform. Paired with its dedicated test kit, the Accelerate PhenoTest, this system facilitates quick identification and antimicrobial susceptibility testing (AST) for pathogens responsible for severe or healthcare-associated infections, encompassing both Gram-positive and Gram-negative organisms. The PhenoTest is specifically designed to yield crucial ID and AST results for patients suspected of bacteremia or fungemia – life-threatening conditions marked by high morbidity and mortality risks. Established in 1982, the company initially operated as Accelr8 Technology Corporation before adopting its current name, Accelerate Diagnostics, Inc., in December 2012. Its corporate headquarters are located in Tucson, Arizona.
Aandeelprijs
$0.01005
Laatst gesynchroniseerd: 2025-06-09
Marktkapitalisatie
$146.42K
Verandering (1 dag)
-28.21%
Verandering (1 jaar)
0.00%
Land
US
Handel Accelerate Diagnostics, Inc. (AXDX)

Categorie

Winst voor Accelerate Diagnostics, Inc. (AXDX)
Winst in 2026 TTM: 0
Volgens de meest recente financiële verslagen van Accelerate Diagnostics, Inc. bedraagt de huidige winst van het bedrijf 0. In 2026 behaalde het bedrijf een winst van 0, gelijk aan de winst van 2026, die 0 bedroeg. De weergegeven winst op deze pagina is de winst vóór rente en belastingen, oftewel EBIT.
Winstgeschiedenis van Accelerate Diagnostics, Inc. van 2026 tot 2026
Winst aan het einde van elk jaar
Jaar Winst Wijzigen
Niet genoeg gegevens voor de verstrekte datums.
Winst van vergelijkbare bedrijven of concurrenten
Bedrijf Winst Winstverschil Land
$7.51B -
US
$5.15B -
US
$5.56B -
IE
$3.86B -
US
$1.42B -
US